ERIS Lifesciences has appointed Vineet Varma (DIN: 11600100) as an Additional Director (Non-executive, Independent) of the Company for a term of five years, effective from 14 March 2026, subject to the approval of the members.Powered by Capital Market - Live News

ERIS Lifesciences has allotted 19,624 equity shares under ESOP on 12 March 2026. With this allotment, the paid up equity share capital stands increased to Rs. 13,85,42,887/- (13,85,42,887 equity shares of Re. 1/- each).Powered by Capital Market - Live News

Net profit of ERIS Lifesciences rose 19.05% to Rs 99.72 crore in the quarter ended December 2025 as against Rs 83.76 crore during the previous quarter ended December 2024. Sales rose 10.91% to Rs 800.89 crore in the quarter ended December 2025 as against Rs 722.12 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales800.89722.12 11 OPM %35.1634.66 - PBDT232.93197.36 18 PBT162.59116.36 40 NP99.7283.76 19 Powered by Capital Market - Live News

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live News

The board of ERIS Lifesciences at its meeting held on 24 November 2025 has approved the acquisition of balance 30% of the total share capital of Swiss Parenterals, a subsidiary of the Company. Further, the board has approved the issuance of up to 23,06,372 equity shares of the Company on preferential basis to discharge the consideration for acquisition of 30% stake in Swiss Parenterals. Powered by Capital Market - Live News